RT Journal Article
SR Electronic
T1 Weekly Paclitaxel as Second/Third-line Treatment in Advanced Non-small Cell Lung Cancer Patients: Efficacy and Tolerability
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 4611
OP 4614
VO 25
IS 6C
A1 CARLOS CAMPS
A1 CRISTINA CABALLERO
A1 ANA BLASCO
A1 MARIA JOSE SAFONT
A1 ALFONSO BERROCAL
A1 JAVIER GARDE
A1 ASUNCION JUAREZ
A1 RAFAEL SIRERA
A1 ROY M. BREMNES
YR 2005
UL http://ar.iiarjournals.org/content/25/6C/4611.abstract
AB Background: The aim of the present study was to evaluate the efficacy and toxicity of weekly paclitaxel as second- or third-line treatment in non-small cell lung cancer (NSCLC) patients. Materials and Methods: The outcome measured in 37 patients were: response rates, symptom relief (dyspnoea, asthenia and pain), toxicity, overall survival (OS) and time to progression (TTP). Results: Objective response was seen in 8%, stable disease in 27% and disease progression in 62%. Three paclitaxel courses reduced the frequency of WHO grade 2-3 dyspnoea and asthenia from 38% and 43% to 13.5% and 8.1%, respectively. Moderate to severe pain (VAS score 3-8) was reduced from 35.1% to 24.3%. Median OS was 38 weeks and TTP 12 weeks. Haematological toxicity included anaemia (30% grade 2-3) and neutropenia (8% grade 3). Non-haematological toxicity included peripheral neuropathy (41% grade 1-2). Conclusion: In the routine outpatient setting, weekly paclitaxel is feasible, active and well-tolerated as second/third-line chemotherapy in patients with advanced NSCLC. Copyright© 2005 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved